HSP90AA1 and cancer: Inhibition of Hsp90 would lead to the proteasomal degradation of a large number of oncogenic client proteins, offering an additional favour of combinatorial impact on multiple oncogenic pathways and amelioration of all the cancer attributing traits, including proliferation, evasion of apoptosis, immortalization, invasion, angiogenesis and metastasis [9].